Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Holding MTNB?
Track your performance easily
MTNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.09 - $0.89
Previous Close$0.09
Volume2.78M
Average Volume (3M)1.15M
Market Cap
$23.40M
Enterprise Value$12.33M
Total Cash (Recent Filing)$14.31M
Total Debt (Recent Filing)$3.24M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 06, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding250,816,164
10 Day Avg. Volume2,868,735
30 Day Avg. Volume1,150,687
Standard Deviation0.26
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)21.35
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.25
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$1.00Price Target Upside971.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Matinas BioPharma News
PremiumCompany Announcements
Matinas BioPharma Releases Updated Corporate Presentation
PremiumPre-Earnings
Is MTNB a Buy, Before Earnings?
Ownership Overview
12.66%
Insiders
4.54% Mutual Funds
12.06% Other Institutional Investors
70.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MTNB FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was $0.09 and its highest was $0.89 in the past 12 months.
What is Matinas BioPharma’s market cap?
Currently, no data Available
When is Matinas BioPharma’s upcoming earnings report date?
Matinas BioPharma’s upcoming earnings report date is Nov 06, 2024 which is in 67 days.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on Aug 14, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.025 by $0.005.
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Undervalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate is -$0.02.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 250,816,160 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.025. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Among the largest hedge funds holding Matinas BioPharma’s share is Highbridge Capital Management LLC. It holds Matinas BioPharma’s shares valued at 2M.
---
Matinas BioPharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.00 (971.81% Upside)
$1.00 (971.81% Upside)
Blogger Sentiment
Bullish
MTNB Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Fundamentals
Return on Equity
-97.59%
Trailing 12-Months
Asset Growth
-28.39%
Trailing 12-Months
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
---
MTNB Earnings Call
Q2 2024
0:00 / 0:00
---
MTNB Stock 12 Month Forecast
Average Price Target
$1.00
▲(971.81% Upside)
Technical Analysis
Best Analysts Covering MTNB
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-56.86%
reiterated a buy rating 16 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.86% per trade.
---